CN115737550A - Preparation method of ganoderma spore polysaccharide injection - Google Patents
Preparation method of ganoderma spore polysaccharide injection Download PDFInfo
- Publication number
- CN115737550A CN115737550A CN202211542163.3A CN202211542163A CN115737550A CN 115737550 A CN115737550 A CN 115737550A CN 202211542163 A CN202211542163 A CN 202211542163A CN 115737550 A CN115737550 A CN 115737550A
- Authority
- CN
- China
- Prior art keywords
- concentrated solution
- polysaccharide injection
- controlling
- flow rate
- collecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 27
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 27
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 27
- 238000002347 injection Methods 0.000 title claims abstract description 22
- 239000007924 injection Substances 0.000 title claims abstract description 22
- 241000222336 Ganoderma Species 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000243 solution Substances 0.000 claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 13
- 239000012528 membrane Substances 0.000 claims abstract description 13
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 12
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001728 nano-filtration Methods 0.000 claims abstract description 8
- 238000007789 sealing Methods 0.000 claims abstract description 6
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 238000011049 filling Methods 0.000 claims abstract description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000001471 micro-filtration Methods 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 6
- 238000005265 energy consumption Methods 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000003960 organic solvent Substances 0.000 abstract description 2
- 239000003054 catalyst Substances 0.000 abstract 2
- 210000002421 cell wall Anatomy 0.000 abstract 1
- 238000004440 column chromatography Methods 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 230000008020 evaporation Effects 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 6
- 229960005305 adenosine Drugs 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 2
- 229930182735 Ganoderic acid Natural products 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000028872 Progressive muscular dystrophy Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The invention discloses a preparation method of a lingsporing polysaccharide injection. The method mainly comprises the following steps: 1) Breaking cell wall of Ganoderma spore powder, purifying with water, and decocting. 2) Microfiltering the extractive solution at 15-25 deg.C with flow rate of 0.3-0.4m 3 H is the ratio of the total weight of the catalyst to the total weight of the catalyst. 3) Ultrafiltering the filtrate at 15-25 deg.C with flow rate of 0.4-0.6m 3 H is used as the reference value. 4) Performing nanofiltration on the ultrafiltrate at 15-25 ℃, and controlling the volume of the concentrated solution to be 1/6-1/5 of the extracting solution. 5) And preparing the concentrated solution, filling and sealing, and sterilizing to obtain the ganoderma lucidum polysaccharide injection. The invention adopts the membrane combinationThe filtering technology achieves the purposes of improving the purity of the extract and ensuring the yield of the effective components. The technology replaces the traditional organic solvent and resin column chromatography and the traditional evaporation concentration or vacuum concentration, and achieves the purposes of environmental protection, low cost and low energy consumption. The invention is more suitable for industrial mass production and can effectively control the quality and purity of the ganoderma spore polysaccharide injection.
Description
The application is a divisional application with an application date of 2015, 07 and 09 and an application number of 201510406359.3 named as "preparation process of a lingosporin polysaccharide injection".
Technical Field
The invention relates to a preparation method of a lingsporing polysaccharide injection, belonging to the field of biological medicine.
Background
The ganoderma spore polysaccharide injection is prepared by extracting ganoderma spore powder treated by a wall breaking technology to prepare ganoderma spore polysaccharide, is used for treating malignant tumors, low immune function diseases, muscular dystrophy, myasthenia gravis and other diseases, and has important clinical value.
The preparation process of the lingpo polysaccharide injection has no literature report, and the traditional extraction method and technology have various defects of low product yield, high cost, large pollution, difficult industrialization and the like.
Chinese patent CN1579414A discloses a lingbao polysaccharide for injection and its preparation process, the final product is powder injection, the first half of its preparation adopts alcohol precipitation and chromatography technology, the process route uses a large amount of organic solvent, generates a large amount of waste water, the process steps are tedious, the key defect is that the adenosine content loss in the final product is very large, so its production cost is high, yield is low, it is not environmental protection, quality is unstable and results in the final product curative effect is not good enough.
Disclosure of Invention
The invention aims to solve the problems of large solvent usage amount, high energy consumption, complex process, unstable quality, loss of effective components and the like in the traditional extraction technology by adopting a three-stage combined filtration technology. Provides a set of preparation method which has simple process, stable medicine quality, low energy consumption, environmental protection and suitability for industrialization and aims at providing safe and effective medicine for clinic.
In order to achieve the purpose, the invention adopts the following technical scheme:
a preparation method of a lingosporin polysaccharide injection comprises the following steps:
1) Adding wall-broken Ganoderma spore powder and purified water, and decocting; the weight ratio of the wall-broken ganoderma lucidum spore powder to the purified water is 1: 8-1: 10, decocting for 4 times at the decoction temperature of 80-90 ℃;
2) Mixing extractive solutions, microfiltering at 15-25 deg.C, and controlling flow rate at 0.3-0.4m 3 /h；
3) Ultrafiltering the filtrate at 15-25 deg.C, and controlling flow rate at 0.4-0.6m 3 H; the cutoff molecular weight of an ultrafiltration membrane adopted by ultrafiltration is more than 60 kDa-80 kDa;
4) Performing nanofiltration on the ultrafiltrate at 15-25 ℃, collecting a nano-concentrated solution, and controlling the volume of the nano-concentrated solution to be 1/6-1/5 of the extracting solution;
5) And preparing the concentrated solution, filling and sealing, and sterilizing to obtain a finished product of the ganoderma spore polysaccharide injection.
Preferably, the steps are:
1) Adding 40kg of wall-broken Ganoderma spore powder and 320kg of purified water into the extractor, heating to 90 deg.C, decocting and extracting for 4 times, each for 2 hr;
2) Mixing the extractive solutions obtained 4 times, cooling to 15-25 deg.C, and starting microfiltration with flow rate of 0.3-0.4m 3 H, collecting the micro-filtrate into a storage tank;
3) Ultrafiltering the micro-filtrate with ultrafiltration membrane at 15-25 deg.C and 0.4-0.6m 3 Collecting ultrafiltrate into a storage tank; the molecular weight cut-off of the ultrafiltration membrane adopted by ultrafiltration is more than 80 kDa;
4) Controlling the temperature of the ultrafiltrate to be 15-25 ℃ for nanofiltration, collecting concentrated solution, and controlling the volume of the concentrated solution to be 1/6 of the extracting solution;
5) And preparing the concentrated solution, filling and sealing, and sterilizing to obtain a finished product of the ganoderma spore polysaccharide injection.
The most obvious characteristics of the invention are as follows:
1. the three-stage filtration is adopted for combined use, so that the high yield of the effective components of the extract, the stable product quality, the low energy consumption, the low cost and the environmental protection are ensured. The whole process is relatively simple and easy to operate, pollution is greatly reduced compared with the traditional method, comprehensive cost is reduced, and the method is more suitable for industrial production.
2. The product adopts wall-broken ganoderma lucidum spore powder, ganoderma lucidum spores are processed by a wall-breaking technology, the wall-broken ganoderma lucidum spore is more suitable for direct absorption of intestines and stomach of a human body, essence of ganoderma lucidum is condensed, and the ganoderma lucidum spore powder has all genetic materials and health care effects of ganoderma lucidum.
It is rich in polysaccharide, triterpenoid ganoderic acid, adenosine, natural organic germanium, and trace element selenium. Ganoderma polysaccharides can enhance immune system function, and prevent and treat tumor and cancer; reducing blood pressure and preventing the generation of cardiovascular epidemic diseases; stimulating the secretion of insulin and reducing the blood sugar concentration; accelerating blood microcirculation, improving oxygen supply capacity of blood, reducing ineffective oxygen consumption of organism in static state, eliminating free radicals in vivo, improving cell membrane sealing degree of organism, resisting radiation, improving DNA, RNA and protein synthesis capacity of liver, bone marrow and blood, and prolonging life. The pharmacological activities of ganoderma lucidum are mostly related to ganoderma lucidum polysaccharide; the triterpene ganoderic acid has effects of improving microcirculation, reducing cholesterol, preventing angiosclerosis, strengthening liver, spleen and stomach functions, and strengthening digestive organs; the natural organic germanium can enhance the blood supply of human body, promote blood metabolism, eliminate free radicals in vivo, prevent cell aging, and extract electrons from cancer cells to lower the potential, thereby inhibiting cancer cell deterioration and diffusion; adenosine can inhibit platelet aggregation and prevent thrombosis; the trace element selenium can be used for preventing cancer, relieving pain, preventing prostate diseases, and improving sexual function by combining with vitamin C.
The research shows that: the injection has good therapeutic effect on neurosis, polymyositis, dermatomyositis, atrophic muscular dystrophies, progressive muscular dystrophy, and various diseases caused by immunologic function.
Drawings
FIG. 1 is a process flow diagram of the preparation method of the present invention.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are commercially available.
Example 1
1) Adding 40kg of wall-broken Ganoderma spore powder and 320kg of purified water into the extractor, heating to 90 deg.C, decocting and extracting for 4 times, each for 2 hr.
2) Mixing the extractive solutions obtained 4 times, cooling to 15-25 deg.C, and micro-filtering with flow rate of 0.3-0.4m 3 And h, collecting the micro-filtrate in a storage tank.
3) Ultrafiltering the micro-filtrate with ultrafiltration membrane (the interception range of the membrane is above 80 kDa), controlling the temperature at 15-25 deg.C and the flow rate at 0.4-0.6m 3 And h, collecting the ultrafiltrate into a storage tank.
4) And (3) controlling the temperature of the ultrafiltrate to be 15-25 ℃ for nanofiltration, collecting a nano-concentrated solution, and controlling the volume of the nano-concentrated solution to be 1/6 about 50L of the extracting solution.
5) The concentrated solution is prepared, encapsulated and sterilized to obtain the finished product (2 mL/per unit) of the lingosporin polysaccharide injection, and the yield of the lingosporin polysaccharide reaches 95 percent and the yield of adenosine reaches 90 percent through inspection.
Example 2
1) Adding 40kg of wall-broken Ganoderma spore powder and 320kg of purified water into the extractor, heating to 90 deg.C, decocting and extracting for 4 times, each for 2 hr.
2) Mixing the extractive solutions obtained 4 times, cooling to 15-25 deg.C, and starting microfiltration with flow rate of 0.3-0.4m 3 And h, collecting the micro-filtrate in a storage tank.
3) Ultrafiltering the micro filtrate with ultrafiltration membrane (the interception range of the membrane is above 60 kDa), controlling temperature at 15-25 deg.C and flow rate at 0.4-0.6m 3 And h, collecting the ultrafiltrate into a storage tank.
4) And (3) controlling the temperature of the ultrafiltrate to be 15-25 ℃ for nanofiltration, collecting a nano-concentrated solution, and controlling the volume of the nano-concentrated solution to be 1/6 about 50L of the extracting solution.
5) The concentrated solution is prepared, encapsulated and sterilized to obtain the finished product (2 mL/per unit) of the lingosporin polysaccharide injection, and the yield of the lingosporin polysaccharide reaches 88 percent and the yield of adenosine reaches 85 percent through inspection.
Example 3
1) Adding 40kg of wall-broken Ganoderma spore powder and 320kg of purified water into the extractor, heating to 90 deg.C, decocting and extracting for 4 times, each for 2 hr.
2) Mixing the extractive solutions obtained 4 times, cooling to 15-25 deg.C, and starting microfiltration with flow rate of 0.3-0.4m 3 And h, collecting the micro-filtrate in a storage tank.
3) Ultrafiltering the micro filtrate with ultrafiltration membrane (the interception range of the membrane is above 70 kDa), controlling temperature at 15-25 deg.C and flow rate at 0.4-0.6m 3 And h, collecting the ultrafiltrate into a storage tank.
4) And (3) controlling the temperature of the ultrafiltrate to be 15-25 ℃ to carry out nanofiltration, collecting the sodium concentrated solution, and controlling the volume of the sodium concentrated solution to be 1/6 about 50L of the extracting solution.
5) Preparing the concentrated solution, encapsulating, and sterilizing to obtain the finished product (2 mL/per unit) of the lingbao polysaccharide injection, wherein the yield of lingbao polysaccharide reaches 91% and the yield of adenosine reaches 88%.
Claims (2)
1. A preparation method of lingsporing polysaccharide injection is characterized by comprising the following steps:
1) Adding wall-broken Ganoderma spore powder and purified water, and decocting; the weight ratio of the wall-broken ganoderma lucidum spore powder to the purified water is 1: 8-1: 10, decocting for 4 times at the decocting temperature of 80-90 ℃;
2) Mixing extractive solutions, microfiltering at 15-25 deg.C, and controlling flow rate at 0.3-0.4m 3 /h；
3) Ultrafiltering the filtrate at 15-25 deg.C, and controlling flow rate at 0.4-0.6m 3 H; the molecular weight cut-off of the ultrafiltration membrane adopted by ultrafiltration is more than 60 kDa-80 kDa;
4) Performing nanofiltration on the ultrafiltrate at 15-25 ℃, collecting a nano-concentrated solution, and controlling the volume of the nano-concentrated solution to be 1/6-1/5 of the extracting solution;
5) And (3) preparing the sodium concentrated solution, filling and sealing, and sterilizing to obtain a finished product of the ganoderma lucidum polysaccharide injection.
2. The preparation method of the lingosporin polysaccharide injection as claimed in claim 1, which comprises the steps of:
1) Adding 40kg of wall-broken Ganoderma spore powder and 320kg of purified water into the extractor, heating to 90 deg.C, decocting and extracting for 4 times, each for 2 hr;
2) Mixing the extractive solutions obtained 4 times, cooling to 15-25 deg.C, and starting microfiltration with flow rate of 0.3-0.4m 3 Collecting the micro-filtrate into a storage tank;
3) Ultrafiltering the micro-filtrate with ultrafiltration membrane at 15-25 deg.C and 0.4-0.6m 3 Collecting ultrafiltrate into a storage tank; the molecular weight cut-off of the ultrafiltration membrane adopted by ultrafiltration is more than 80 kDa;
4) Controlling the temperature of the ultrafiltrate to be 15-25 ℃ for nanofiltration, collecting concentrated solution, and controlling the volume of the concentrated solution to be 1/6 of the extracting solution;
5) And preparing the concentrated solution, filling and sealing, and sterilizing to obtain a finished product of the ganoderma spore polysaccharide injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211542163.3A CN115737550A (en) | 2015-07-09 | 2015-07-09 | Preparation method of ganoderma spore polysaccharide injection |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406359.3A CN106309469A (en) | 2015-07-09 | 2015-07-09 | Preparation technique of ganoderma lucidum polysaccharide injection |
| CN202211542163.3A CN115737550A (en) | 2015-07-09 | 2015-07-09 | Preparation method of ganoderma spore polysaccharide injection |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510406359.3A Division CN106309469A (en) | 2015-07-09 | 2015-07-09 | Preparation technique of ganoderma lucidum polysaccharide injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115737550A true CN115737550A (en) | 2023-03-07 |
Family
ID=57725376
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510406359.3A Pending CN106309469A (en) | 2015-07-09 | 2015-07-09 | Preparation technique of ganoderma lucidum polysaccharide injection |
| CN202211542163.3A Pending CN115737550A (en) | 2015-07-09 | 2015-07-09 | Preparation method of ganoderma spore polysaccharide injection |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510406359.3A Pending CN106309469A (en) | 2015-07-09 | 2015-07-09 | Preparation technique of ganoderma lucidum polysaccharide injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN106309469A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107397765A (en) * | 2017-07-31 | 2017-11-28 | 广东省微生物研究所（广东省微生物分析检测中心） | A kind of sporoderm-broken ganoderma spores extract and its extracting method and application |
| CN108042523A (en) * | 2017-12-21 | 2018-05-18 | 同济大学 | Glycine betaine（Betaine）Application in the drug as prevention and treatment multiple sclerosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1266164C (en) * | 2003-07-25 | 2006-07-26 | 中国科学院上海有机化学研究所 | Lucid ganoderma spore powder polysaccharide, production method and use |
| CN1628693A (en) * | 2003-12-16 | 2005-06-22 | 沈阳科思科技发展有限公司 | Glossy ganoderma preparation containing main active substance of glossy ganoderma herb and preparing method thereof |
| CN1261104C (en) * | 2004-03-04 | 2006-06-28 | 江卫世 | Glossy-ganoderma-spore polysaccharide for injection and its preparation process |
-
2015
- 2015-07-09 CN CN201510406359.3A patent/CN106309469A/en active Pending
- 2015-07-09 CN CN202211542163.3A patent/CN115737550A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 严焕雄等: ""灵芝孢子粉中多糖的制备工艺研究"", 《中国执业药师》, vol. 11, no. 1, pages 16 - 19 * |
| 胡亚芹等: ""超滤膜技术在多糖提取方面的应用"", 《生物技术通讯》, vol. 16, no. 2, pages 228 - 230 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106309469A (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100992800B1 (en) | A process for preparing novel processed ginseng or extract thereof showing increased amount of minor ginsenosides | |
| CN113150867B (en) | Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes | |
| CN101747446B (en) | Method for extracting anti-fatigue acidic ginseng polysaccharide | |
| CN101961371B (en) | Method for extracting and separating ginsenoside, flavone and polysaccharide from sweet gynostemma pentaphylla | |
| CN103819577B (en) | A kind of preparation method of spirulina polysaccharide | |
| CN104277134B (en) | A kind of preparation method and applications of the dictyophora fungus polysaccharide-chelates of zinc with anti-tumor activity | |
| CN101461543B (en) | Deep-processing method of deer blood | |
| CN105079046A (en) | Whole ganoderma lucidum anti-tumor soft capsules and preparation method thereof | |
| CN103073648A (en) | Method for increasing antioxidation activity of flammulina velutipes polysaccharide | |
| CN102532339A (en) | Method for selenizing pilose asiabell root polysaccharides and application of product | |
| CN109608557A (en) | Polysaccharides extracts Isolation and purification method, Lycium chinense glycopeptide and preparation method | |
| CN102154428B (en) | Method for preparing ginsenoside Rh2 | |
| CN105400845A (en) | Technology for producing radix astragali polysaccharide by utilization of microbial fermentation technology | |
| CN105418785B (en) | A kind of production method of Radix Et Caulis Acanthopanacis Senticosi polysaccharide and its application | |
| CN115737550A (en) | Preparation method of ganoderma spore polysaccharide injection | |
| CN111248440B (en) | Functional jasmine flower oligosaccharide oral liquid and application thereof | |
| CN105497109A (en) | Process for producing milkvetch root total flavones through microbial fermentation technology | |
| CN102229594A (en) | Method of dual-aqueous phase system for purifying polygala root xanthonoid compound | |
| CN102174613A (en) | Separation and purification method of lactobacillus polysaccharide | |
| CN103059086A (en) | Extraction and purification method of cordycepin from cordyceps militaris solid mediums | |
| CN111333747A (en) | Preparation method of lentinan | |
| CN101717806A (en) | Integrated peptidoglycan and preparation method thereof | |
| CN102688248A (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN101926842A (en) | Medicinal composition prepared from raw materials containing snow lotus and fermented cordyceps fungal powder | |
| CN101358222A (en) | Method for microwave auxiliarily extracting antiradiation polysaccharide using potentilla anserine as feedstock |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |